Ribonucleic acid, or RNA, has emerged as a hot new field after mRNA and miRNA discoveries won Nobel Prizes in 2023 and 2024, respectively, drawing attention to its scientific value and industrial ...

New funding led by Goldcrest Capital and Godfrey Capital to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies JUN_01 would be the first ever candidate to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose ...

When I first wrote “Vector databases: Shiny object syndrome and the case of a missing unicorn” in March 2024, the industry was awash in hype. Vector databases were positioned as the next big thing — a ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

Google long touted the need for factual accuracy on its platforms, but a letter submitted to Congress this week demonstrates how the tech company is shifting to prioritize "free expression." Google's ...

Re “Colleges Must Keep Hosting Difficult Speakers,” by Laura Ann Rosenbury (Opinion guest essay, Sept. 18): I agree with Ms. Rosenbury when she writes that free speech must be protected on college ...

California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease. Aditum has paid Mabwell $12 million ...